Imara to merge with Enliven; Enliven stockholders to own ~84% of combined company

Enliven Therapeutics, Inc.

Enliven valued at $324.6M plus $164.5M financing; Imara valued at net cash plus $10M.
Pre-merger Imara stockholders to own ~16% of combined co; CVRs tied to asset sale/IMR-261.
Concurrent $164.5M Enliven PIPE; closing conditioned on Imara asset sale, HSR, stockholder votes.
Board: 8 Enliven designees, 1 Imara (CEO Rahul Ballal); reverse stock split planned.
Termination fees: Imara pays $3M, Enliven pays $9.75M under specified conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.